CHARLOTTESVILLE, Va., June 10 /PRNewswire/ -- Diffusion Pharmaceuticals
LLC, a clinical-stage drug-development company commercializing new drugs
for the treatment of life-threatening unmet medical needs, today announced
the addition of Mark T. Giles to its Board of Directors.
(Photo: http://www.newscom.com/cgi-bin/prnh/20080610/NETU101 )
Mr. Giles is the Chairman of the Board of Virginia National Bank in
Charlottesville, Virginia. He also is the managing member of Panda
Holdings, LLC, which engages in the investment and management of private
capital. In addition to VNB and Diffusion Pharmaceuticals LLC, Mr. Giles is
a director of GreenVolts, Inc. and Avir Sensors, LLC.
From January 1998 to June 2007, Mr. Giles served as the founding
President and CEO of Virginia National Bank and from January 1995 through
1997, he served as President of Sterling Bank and its parent company,
Sterling Bancshares, Inc., a publicly-traded Houston, Texas financial
institution. Prior to joining Sterling, he had been President of Charter
National Bank- Houston and its parent company, Charter Bancshares, Inc., a
publicly traded Houston financial institution he had joined in 1986 as
Chief Financial Officer. Until 1986, he had practiced law with the banking
group of the Houston law firm Bracewell & Guiliani, LLP. In
Charlottesville, Mr. Giles chairs the boards of Computers4Kids and the
Thomas Jefferson Area United Way. He also is a director of Martha Jefferson
Hospital.
In 1977, Mr. Giles received a BS degree in Finance from the McIntire
School of Commerce at the University of Virginia and was recipient of the
faculty's outstanding finance major award. He received a J.D. degree from
the University of Virginia School of Law in 1980.
"We are fortunate that Mr. Giles has decided to join Diffusion
Pharmaceuticals' Board of Directors," said David G. Kalergis, CEO. "His
extensive experience further strengthens our business and financial
leadership capabilities."
About Diffusion Pharmaceuticals LLC
Diffusion Pharmaceuticals LLC is a clinical-stage drug-development
company commercializing a family of first-in-class drug candidates to treat
serious or life-threatening medical conditions. These proprietary small
molecules use a novel method of action to enhance oxygen diffusion to
oxygen deprived (hypoxic) tissue. Potential clinical applications include
cancer, critical care uses such as trauma, hemorrhage, stroke and heart
attack, as well as chronic conditions such as peripheral arterial and
vascular disease, cardiovascular disease, and respiratory disorders.
Enhanced diffusion of oxygen into hypoxic tissue has an important
application in oncology by improving the efficacy of radiation therapy in
cancerous tumors. A Phase 1 study for its lead molecule, trans sodium
crocetinate (TSC), in healthy subjects was successfully completed in 2007.
The company is now initiating proof-of-concept and dose-finding studies in
cancer patients undergoing radiation therapy and in peripheral arterial
disease patients suffering from intermittent claudication. Diffusion
Pharmaceuticals, which is privately held, is located in Charlottesville,
Virginia. For more information, visit http://www.diffusionpharma.com.
SOURCE Diffusion Pharmaceuticals LLC
 back to top
Related links:
http://www.diffusionpharma.com
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20080610/NETU101
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Tracey Linkous, Director of Communications of
Diffusion Pharmaceuticals LLC, +1-434-220-0718,
tlinkous@diffusionpharma.com
|
